BioMerieux Change in Accounts Receivable 2017-2024 | BMXMF

BioMerieux change in accounts receivable for the twelve months ending December 31, 2024 was $0M, a 0% increase year-over-year.

  • BioMerieux annual change in accounts receivable for 2024 was $-0.058B, a 291.89% increase from 2023.
  • BioMerieux annual change in accounts receivable for 2023 was $-0.015B, a 90.33% decline from 2022.
  • BioMerieux annual change in accounts receivable for 2022 was $-0.153B, a 649.42% decline from 2021.

BioMerieux Change in Accounts Receivable 2017-2024 | BMXMF

  • BioMerieux annual change in accounts receivable for 2024 was $-0.058B, a 291.89% increase from 2023.
  • BioMerieux annual change in accounts receivable for 2023 was $-0.015B, a 90.33% decline from 2022.
  • BioMerieux annual change in accounts receivable for 2022 was $-0.153B, a 649.42% decline from 2021.
Related Stocks
Company NameMarket
Cap
Danaher (DHR)$148.7B
CVS Health (CVS)$90.3B
Elevance Health (ELV)$70.7B
Cencora (COR)$55.9B
DiDi Global (DIDIY)$26.8B
Labcorp Holdings (LH)$22.9B
Natera (NTRA)$22.3B
EUROFINS SCIENT (ERFSF)$15B
ICON (ICLR)$13.9B
Medpace Holdings (MEDP)$13.1B
CochLear (CHEOY)$12.8B
Solventum (SOLV)$12.6B
Viatris (VTRS)$12.3B
Caris Life Sciences,�Inc (CAI)$10.8B
Revvity (RVTY)$10.7B
Avantor (AVTR)$9B
Charles River Laboratories (CRL)$8.1B
Sonic Healthcare (SKHHY)$7.7B
HealthEquity (HQY)$7.6B
Bausch + Lomb (BLCO)$5.1B
Sotera Health (SHC)$4.7B
BrightSpring Health Services (BTSG)$4.3B
Amplifon S.p.A (AMFPF)$3.9B
GeneDx Holdings (WGS)$3.5B
KindlyMD (NAKA)$3.4B
Alignment Healthcare (ALHC)$3.1B
Concentras Parent (CON)$3B
Surgery Partners (SGRY)$3B
Organon (OGN)$2.4B
Premier (PINC)$2.1B